|
| |
| Evaluation of polyneuropathy |
| Time course |
 | Acute & subacute:
 | Acute: days to 4 weeks |
 | Subacute:
4 to 8 weeks
|
 | Suspect
 | GBS: Acute inflammatory
demyelinating polyradiculoneuropathy |
 | Porphyria |
 | Acute toxic exposure (arsenic) |
 | Mononeuritis multiplex, such as from vasculitis |
 | Proximal diabetic neuropathy |
 | Idiopathic plexopathy |
 | Paraneoplastic sensory neuronopathy |
|
|
 | Chronic: greater than 8 weeks:
 | Static |
 | Relapsing: CIDP and porphyria. |
 | Progressive |
|
|
| Symmetric vs asymmetric polyneurpathy? |
|
|
| Inherited or Acquired ? |
Hereditary Neuropathy:
 | Long history (years) and symmetric symptoms since onset.
|
 | Pes cavus and hammer toes are signs of inherited neuropathy and should be
specifically sought. |
 | A negative family history does not exclude inherited neuropathy.
 | Symptoms may be mild and unrecognized in family members.
|
 | Recessive inheritance: implies that neither parent is affected. |
 | Paternity may not be as clear as it appears. |
|
|
| History |
 | Medications & toxic exposure, especially alcohol |
 | Concomitant medical problems:
 | Infections or vaccinations |
 | Constitutional symptoms: joint pain, rash, fever, weight loss
|
|
 | Brief occupational history |
|
| Diagnostic tests |
 | Blood test:
 | SMAC, CBC, glycosylated
hemoglobin, TSH, ESR, Rheumatoid factor, ANA, serum
(and preferably urine) protein immunoelectrophoresis. |
 |
Vitamin B12 level
 |
if the result is borderline (200-300 pg/ml)
methylmalonic acid and homocysteine levels
should be tested. |
|
 |
2 hour glucose tolerance test |
|
 | Chest X ray: malignancy, Sarcoid |
 | Electrodiagnostic study |
 |
Special diagnostic tets:
 |
Evidence of dry eyes or mouth
|
 |
Systemic evidence of a
connective tissue disease (e.g. rash, Raynauds phemonoma,
arthritis)
 |
connective tissue disease
evaluation including cryoglobulins and hepatitis C serologies. |
|
 |
Suspect multifocal motor neuropathy
 |
GM1 |
|
 |
Suspected CIDP
 |
MAG |
|
 | Suspect toxic neuropathy
 | Urine heavy metals |
|
 |
If EDX is negative
 |
The most sensitive means of proving the
presence of neuropathy is skin biopsy |
 |
measure intraepidermal nerve
fiber density (IENF) |
 |
abnormal in approximately 90% of patients with neuropathy. |
|
|
 | More on Autoantibody testing |
|
| Further reading |
 | Chalk, CH. Neurologic Clinics. Vol 15. No 3. Aug 1997 |
|
Return to Neuromuscular disease info center
|